Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06989918 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MHB018A Treatment in Patients With Active Thyroid Eye Disease

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Jul 31, 2026 → Dec 2026
See other at-risk trials from Minghui Pharmaceutical (Hangzhou) Ltd

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 4 more changesShow less
    • Primary completion pushed from Jul 31, 2026 to Dec 2026
    • Eligibility criteria expanded, about 32 words
    • Secondary endpoints: details revised at 4 of 8 entries
    • Site details revised
  2. Primary completion date: Jan 31, 2027 to Jul 31, 2026
    • Study completion date: Jul 31, 2028 to Jul 31, 2027
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Aug 1, 2025 to Jul 22, 2025
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered q4W for 6 months, in comparison to placebo, in the treatment of participants suffering from active TED.
Trial Details
NCT Number NCT06989918
Lead Sponsor Minghui Pharmaceutical (Hangzhou) Ltd
Conditions
(from sponsor)		 Thyroid Associated Ophthalmopathies
Related terms Graves Ophthalmopathy
Enrollment 108 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov